Esperion Therapeutics Inc Quick Ratio (ESPR) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
ESPR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 0.52 below Esperion Therapeutics Inc 's average Quick Ratio.
Within Major Pharmaceutical Preparations industry 383 other companies have achieved higher Quick Ratio than Esperion Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 1797 to 2280.
In a bid to foster continued innovation and attract top-tier talent, Esperion, a leading pharmaceutical company based in Ann Arbor, Michigan, has recently made a significant move. On February 13, 2024, the company granted 66 new employees a total of 204,900 restricted stock units (RSUs) under the Esperion 2017 Inducement Equity Incentive Plan. This latest development is not only a strategic move to bolster the company s research and development efforts but also highlights Esperion s commitment to nurturing a skilled workforce essential for long-term success. Esperion s Impressive Inducement Grants: Through the 2017 Inducement Equity Incentive Plan, Esperion seeks to incentivize and reward employees who demonstrate exceptional dedication, expertise, and strategic value to the company. The granting of 204,900 RSUs to 66 new employees showcases Esperion s proactive approach to attracting top talent in a highly competitive industry. The Significance of RSUs: Restricted stock units (RSUs) serve as a valuable tool for businesses to attract and retain exceptional employees. Unlike traditional stock options, RSUs are actual shares of the company s stock that are granted to employees at a designated vesting period in the future. By offering RSUs, Esperion aligns the interests of its employees with the long-term success and growth of the organization. This approach ensures that employees are motivated to contribute their best efforts towards achieving the company s goals.
Esperion Announces Successful Pricing of $85.1 Million Common Stock Public Offering, Reinforcing Financial Strength ANN ARBOR, Mich., Jan. 18, 2024 - Esperion Therapeutics, Inc. (Nasdaq: ESPR) has recently unveiled the pricing details of its highly anticipated underwritten public offering. This transformative event marks a significant milestone for the biopharmaceutical company, demonstrating their dedication to strengthening their financial position and supporting their strategic initiatives. The offering involves 56,700,000 shares of common stock, initiated at a public offering price of $1.50 per share, prior to underwriting discounts and commissions. Esperion is offering all of the shares of common stock, with an option for the underwriters to purchase an additional 8,505,000 shares at the public offering price, adjusted for underwriting discounts and commissions. Gauging the remarkable investor confidence in Esperion s future prospects, the gross proceeds from the offering, before deducting underwriting discounts, commissions, and other expenses, are estimated at approximately $85.1 million. This figure excludes any exercise of the underwriters option to purchase additional shares.
Esperion Therapeutics Announces Public Offering as it Continues to Pioneer Cardiovascular Therapies ANN ARBOR, Mich., Jan. 18, 2024 - Esperion Therapeutics, Inc. (Nasdaq: ESPR), a leading pharmaceutical company focused on innovative cardiovascular therapies, revealed its plans today to conduct an underwritten public offering of shares of its common stock. This announcement underscores Esperion s commitment to advancing groundbreaking treatments for patients suffering from cardiovascular diseases. Through this offering, Esperion aims to expand its financial resources, enabling the company to further invest in clinical trials, research and development, and product commercialization. The proposed public offering is expected to provide crucial funding for the company s ongoing initiatives and strategic growth objectives. Esperion intends to offer the underwriters a 30-day option to acquire up to 15% additional shares of its common stock at the public offering price, after deducting underwriting discounts and commissions. The final number of shares to be sold, as well as the offering price, will be determined upon completion of the underwriting process.
On the trailing twelve months basis ESPR Cash & cash equivalent grew by 36.22 % in Q1 2026 year on year, faster than Current Liabilities, this led to increase in in Esperion Therapeutics Inc 's Quick Ratio to 0.4, Quick Ratio remained below ESPR average. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Esperion Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2515 to 3939.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
